One Year On Roche’s Herceptin Is Best, Studies Show
This article was originally published in The Pink Sheet Daily
Executive Summary
Two closely watched studies on Herceptin (trastuzumab) suggest neither a shorter nor a longer period of treatment is better at fighting off a recurrence of cancer than the current standard of one year. Roche’s final analysis of HERA and France’s six-month attempt in PHARE were presented Oct. 1 at ESMO.
You may also be interested in...
Genentech Plans Herceptin Early-Stage Breast Cancer Submission
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.